BR9908202A - Dispersão lipossomal de eritropoietina - Google Patents

Dispersão lipossomal de eritropoietina

Info

Publication number
BR9908202A
BR9908202A BR9908202-0A BR9908202A BR9908202A BR 9908202 A BR9908202 A BR 9908202A BR 9908202 A BR9908202 A BR 9908202A BR 9908202 A BR9908202 A BR 9908202A
Authority
BR
Brazil
Prior art keywords
erythropoietin
cholesterol
liposome
liposomal dispersion
lecithin
Prior art date
Application number
BR9908202-0A
Other languages
English (en)
Inventor
Rainer Naeff
Sandro Delmenico
Andre Wetter
Frank-Ulrich Floether
Original Assignee
Cilac Ag Internat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilac Ag Internat filed Critical Cilac Ag Internat
Publication of BR9908202A publication Critical patent/BR9908202A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

Patente de Invenção: <B>"DISPERSãO LIPOSSOMAL DE ERITROPOIETINA"<D>. A presente invenção refere-se a uma formulação com base em lipossoma de eritropoietina compreendendo: (a) uma quantidade eficaz de uma eritropoietina; (b) uma fase lipídica compreendendo: (i) lecitina ou lecitina hidrogenada; (ii) opcionalmente, um composto de lipídeo eletropositivo ou eletronegativo carregado; e (iii) colesterol ou um derivado deste selecionado dos ésteres de colesterol, derivados de glicol de polietileno de colesterol (PEG-colesteróis), e derivados de ácido orgânico de colesteróis; e (c) um tampão de fosfato. A forma dosagem parenteral com base em lipossoma da invenção é preparada por meio de uma técnica de injeção de etanol. A composição evita a necessidade para uso de albumina de soro humano e apresenta estabilidade superior.
BR9908202-0A 1998-02-23 1999-02-12 Dispersão lipossomal de eritropoietina BR9908202A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98103111A EP0937456B1 (en) 1998-02-23 1998-02-23 Erythropoietin liposomal dispersion
PCT/IB1999/000249 WO1999042085A1 (en) 1998-02-23 1999-02-12 Erythropoietin liposomal dispersion

Publications (1)

Publication Number Publication Date
BR9908202A true BR9908202A (pt) 2000-10-24

Family

ID=8231466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908202-0A BR9908202A (pt) 1998-02-23 1999-02-12 Dispersão lipossomal de eritropoietina

Country Status (23)

Country Link
US (2) US6645522B2 (pt)
EP (1) EP0937456B1 (pt)
JP (1) JP4613294B2 (pt)
KR (1) KR100591871B1 (pt)
CN (1) CN1184958C (pt)
AT (1) ATE271376T1 (pt)
AU (1) AU750481B2 (pt)
BR (1) BR9908202A (pt)
CA (1) CA2320072C (pt)
CZ (1) CZ296415B6 (pt)
DE (1) DE69825137T2 (pt)
DK (1) DK0937456T3 (pt)
ES (1) ES2224299T3 (pt)
HU (1) HUP0101026A2 (pt)
IL (2) IL137808A0 (pt)
NO (1) NO20004186D0 (pt)
NZ (1) NZ506429A (pt)
PL (1) PL194502B1 (pt)
PT (1) PT937456E (pt)
RU (1) RU2218914C2 (pt)
SI (1) SI0937456T1 (pt)
SK (1) SK284036B6 (pt)
WO (1) WO1999042085A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0937456T1 (en) * 1998-02-23 2004-12-31 Cilag Ag International Erythropoietin liposomal dispersion
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
DE50014159D1 (de) * 1999-12-22 2007-04-26 Dade Behring Marburg Gmbh Lösungen von humanem Procalcitonin
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
DK1592416T3 (da) * 2003-02-07 2009-04-20 Prometic Biosciences Inc Fedtsyrer med middel kædelængde, glycerider og analoger som stimulatorer af erythropoiesis
WO2005007172A1 (ja) * 2003-07-17 2005-01-27 Otsuka Pharmaceutical Co., Ltd. 配糖体含有リポソーム
BRPI0414887A (pt) * 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
WO2005115337A1 (en) * 2004-05-24 2005-12-08 Polymun Scientific Immunbiologische Forschung Gmbh Superloaded liposomes for drug delivery
KR100684380B1 (ko) 2005-05-24 2007-02-20 한국화학연구원 빗살형 폴리에틸렌글리콜을 결합한 리포솜 및 이의 제조방법
US9119782B2 (en) * 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
US20100310636A1 (en) * 2007-05-09 2010-12-09 Gita Sharma Stearically stabilized unilamilar vesicles, process for preparation thereof and use thereof
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
EP2585046A4 (en) * 2010-06-23 2013-11-06 Brightside Innovations Inc LECITHINTRÄGERVESIKEL AND METHOD FOR THE PRODUCTION THEREOF
EA018472B1 (ru) * 2010-09-15 2013-08-30 Открытое Акционерное Общество "Протек" Частицы, содержащие эритропоэтин, для лечения и профилактики неврологических и гематологических заболеваний и нарушений
MX384232B (es) 2013-03-14 2025-03-14 Jerome J Schentag Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
CN108066288A (zh) * 2014-01-03 2018-05-25 广州市鼍龙生物技术开发有限公司 一种鳄鱼油纳米脂质体及其制备方法
ES2909245T3 (es) * 2014-04-30 2022-05-06 Fujifilm Corp Método para producir liposomas
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
AU598002B2 (en) * 1986-07-15 1990-06-14 Cilag Ltd. Method of preparing single bilayered liposomes
JPH087219B2 (ja) 1992-04-27 1996-01-29 雪印乳業株式会社 リポソーム封入生理活性蛋白質の定量方法
JPH06228012A (ja) 1993-01-29 1994-08-16 Dai Ichi Seiyaku Co Ltd リポソーム製剤
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
WO1995009611A2 (en) * 1993-10-06 1995-04-13 Amgen Inc. Stable protein: phospholipid compositions and methods
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
JP3850468B2 (ja) * 1994-12-28 2006-11-29 中外製薬株式会社 エリスロポエチンのリポソーム製剤
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
SI0937456T1 (en) * 1998-02-23 2004-12-31 Cilag Ag International Erythropoietin liposomal dispersion

Also Published As

Publication number Publication date
JP4613294B2 (ja) 2011-01-12
ES2224299T3 (es) 2005-03-01
DE69825137T2 (de) 2005-07-21
ATE271376T1 (de) 2004-08-15
CZ296415B6 (cs) 2006-03-15
IL137808A0 (en) 2001-10-31
CA2320072C (en) 2009-04-07
SI0937456T1 (en) 2004-12-31
CN1184958C (zh) 2005-01-19
AU2180899A (en) 1999-09-06
RU2218914C2 (ru) 2003-12-20
DE69825137D1 (de) 2004-08-26
CN1298296A (zh) 2001-06-06
JP2002503685A (ja) 2002-02-05
US20040052838A1 (en) 2004-03-18
PL342514A1 (en) 2001-06-18
NO20004186L (no) 2000-08-22
US20020028236A1 (en) 2002-03-07
NZ506429A (en) 2003-03-28
CZ20002959A3 (cs) 2001-10-17
SK284036B6 (sk) 2004-08-03
WO1999042085A1 (en) 1999-08-26
US6645522B2 (en) 2003-11-11
IL137808A (en) 2007-07-24
EP0937456A1 (en) 1999-08-25
CA2320072A1 (en) 1999-08-26
KR20010041152A (ko) 2001-05-15
EP0937456B1 (en) 2004-07-21
HUP0101026A2 (hu) 2001-08-28
PL194502B1 (pl) 2007-06-29
DK0937456T3 (da) 2004-11-08
NO20004186D0 (no) 2000-08-22
PT937456E (pt) 2004-10-29
AU750481B2 (en) 2002-07-18
KR100591871B1 (ko) 2006-06-23
SK12222000A3 (sk) 2001-11-06

Similar Documents

Publication Publication Date Title
BR9908202A (pt) Dispersão lipossomal de eritropoietina
MY111841A (en) Injectable liposomal pharmaceutical preparations
IE851615L (en) Topical composition
AU2001260414A1 (en) Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
KR970706021A (ko) N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
AU1557595A (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
CA2259179A1 (en) Emulsion formulations for hydrophilic active agents
HRP20010779B1 (hr) Farmaceutski pripravak
AU1438699A (en) Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals
BR9911013A (pt) Derivados de pirazol como inibidores da p-38 map quinase
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
TR200002159T2 (tr) NSAI ilaçların verilmesi için topikal bileşimler.
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
HUP9901319A2 (hu) 9-Hidroxi-riszperidon zsírsavészterek vizes szuszpenziói, előállításuk és alkalmazásuk
ATE251443T1 (de) Antimikrobielle kosmetische präparate
ES2124477T3 (es) Uso de un fosfato de ascorbilo y tocoferilo para la preparacion de un medicamento para el tratamiento de la pancreatitis.
BR9807145A (pt) 2-metoxiimino-2-(piridiniloximetil) fenilacetamidas com derivados de ácido carboxìlico no anel de piridina como fungicidas.
BR9915123A (pt) Composição de uma substância farmaceuticamente ativa e dispensador
GEP19991872B (en) Novel Taxoids, Preparations Thereof, and Pharmaceutical Compositions Containing Same
BR9803730A (pt) Preparados farmacêuticos de cilansetron estabilizados contra a racemização.
BR9714047A (pt) Derivados de ácido carboxìlico, uso dos mesmos, combinação destes com um ou mais compostos ativos, preparação de drogas para a administração oral e parenteral, e, antagonista de receptor de endotelina
BR9917006A (pt) ácido niflúmico lipossÈmico - medicamentoantiinflamatório transdérmico
CA2126512A1 (en) Chondroprotective agents
DE69809435D1 (de) Inhibitor- und konservierungsmittelzusammensetzung
WO2001041706A3 (en) Lipid nanotubules for topical delivery

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]